Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals Announces the Presentation of Data at Upcoming Scientific Meetings in July
07/06/2012| 08:05am US/Eastern
Recommend:
0
Clinical trial data from oncology and Alzheimer's disease product
candidates to be presented at EACR, International Head and Neck Cancer
and Alzheimer's Association International Conferences
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty
pharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that data from its Lymphoseek
program were accepted for presentation at the European Association for
Cancer Research (EACR) and the American Head and Neck Society's 8th
International Conference on Head and Neck Cancer Conference. In
addition, data from its AZD4694 program were accepted for presentation
at the Alzheimer's Association International Conference on Alzheimer's
Disease (AAIC). Details of the presentations from the Phase 3 clinical
studies investigating Lymphoseek® (Kit for the Preparation of Technetium
Tc 99m Tilmanocept for Injection) in head and neck cancer, breast
cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its
Alzheimer's Disease candidate, AZD4694 are listed below.
Conference:
European Association for Cancer Research
Date:
July 7-10, 2012
Location:
Barcelona, Spain
Poster Title:
Enhanced Sentinel Node Evaluation in Breast Cancer, Melanoma,
and Head/Neck Squamous Cell Carcinoma Via CD206 Receptor Targeting
With Tc99m-tilmanocept
Author:
Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:
Poster Sessions, July 8-9, 2012
Conference:
Alzheimer's Association International Conference on Alzheimer's
Disease- AAIC
Date:
July 14-19, 2012
Location:
Vancouver, BC, Canada
Presentation Title:
Head to head comparison of 11C-PiB and 18F-AZD4694 for A?
imaging in ageing and dementia
Author:
Christopher Rowe, MD FRACP, Austin Health, Melbourne Australia
Session, Date:
Neuroimaging 1: Amyloid Imaging Validation and Correlation
Sunday, July 15, 2012
Presentation Title:
Amyloid PET Imaging Using AZD4694 and Unusually Brief
Radiotracer Reuptake and Scanning Periods.
Author:
Kewei Chen, PhD, Banner Alzheimer's Institute, Phoenix, AZ
Session, Date:
Novel Tracers and Techniques for Imaging in AD (Session Number: 2860)
Saturday, July 14, 2012
Poster Title:
Comparison of the fluorinated ?-amyloid imaging agents
florbetapir, florbetaben and AZD4694
Author:
Samuel Svensson, AstraZeneca, Södertälje, Sweden
Session, Date:
Poster Session, July 14, 2012
Conference:
8th International Conference on Head
and Neck Cancer (AHNS)
Date:
July 21-25, 2012
Location:
Toronto, Canada
Presentation Title:
Use of a novel receptor-targeted (CD206) radiotracer,
99mTc-tilmanocept, and SPECT/CT for sentinel lymph node (SLN)
mapping in head and neck squamous cell carcinoma (SCCa): Initial
report of institutional experience in an ongoing Phase 3 study
(S146)
Author:
Amit Agrawal, MD, The Ohio State University, Columbus, OH
Date:
Monday, July 23, 13:53 PM
Presentation Title:
99m-Tc-Tilmanocept-Identified Sentinel Lymph Nodes Relative to
the Pathological Status of Non-Sentinel Lymph Nodes in an Elective
Neck Dissection in Cutaneous and Intraoral Head and Neck Squamous
Cell Carcinoma: A Single Institutional Experience (S150)
Author:
Stephen Y. Lai, MD PhD, et al., University of Texas, MD Anderson
Cancer Center, Houston, TX
Date:
Monday, July 23, 14:31 PM
Poster Title:
Clinical Experience at the University of Miami in a Phase 3
Trial Using Receptor Targeted 99mTc-Tilmanocept to Identify and
Evaluate the Pathological Status of Sentinel Lymph Nodes (SLNs)
vs. Elective Neck Dissection (END) for Patients with Intraoral
Squamous Cell Carcinoma
Author:
Francisco Civantos, MD, University of Miami, Miami, FL
Date:
Poster Sessions, July 22-23, 2012
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively
developing three radiopharmaceutical agent platforms - Lymphoseek®,
AZD4694 and RIGScanTM - to help identify the sites and
pathways of undetected disease and enable better diagnostic accuracy,
clinical decision-making and ultimately patient care. Navidea's strategy
is to deliver superior growth and shareholder return by bringing to
market novel radiopharmaceutical agents and advancing the Company's
pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc. Brent Larson, 614-822-2330 Sr.
VP & CFO
Recommend:
